Methods and compositions for use in treatment of patients with autoantibody positive disease
The present invention relates to methods and compositions for use in treatment of patients with autoantibody positive disease. In a specific embodiment, the present invention relates to a method of treating a patient that has an ANA titer of 1:80 or greater and/or greater than or equal to 30 IU/ml of anti-dsDNA antibodies in his/her blood plasma or serum comprising administering a therapeutically effective amount of an immunomodulatory agent, such as an antagonist of Neutrokine-alpha. Additionally provided is a method of reducing the frequency and/or quantity of corticosteroid administration to patients. In preferred embodiments, the patient has systemic lupus erythematosus. Methods for determining if a lupus patient is responding to medical treatment are also provided.
1. A method of reducing the frequency or quantity of corticosteroid administered to a patient with systemic lupus erythematosus comprising:
(a) providing a patient that has systemic lupus erythematosus and to whom a corticosteroid is being administered at a first frequency or quantity;
(b) administering a therapeutically effective amount of an antagonist of Neutrokine-alpha to said patient, wherein the antagonist of Neutrokine-alpha is
an anti-Neutrokine-alpha antibody;
and
(c) administering the corticosteroid to said patient at a second frequency or quantity that is less than the first frequency or quantity.
2. The method of claim 1 wherein the antagonist of Neutrokine-alpha is only administered when the patient has at least one characteristic selected from the group consisting of:
(a) an ANA titer ≧1:80;
(b) ≧30 IU/mL of anti-dsDNA antibodies in his/her blood plasma or serum;
(c) a SELENA SLEDAI score ≧6;
(d) a depressed level of C3 complement factor in his/her blood plasma or serum;
(e) a depressed level of C4 complement factor in his/her blood plasma or serum;
(f) the patient is receiving ≧7.5 milligrams/day of prednisone; and
(g) the patient is receiving or had previously received immunosuppressant therapy for the treatment of lupus-related symptoms.
3. The method of claim 2 wherein the antagonist of Neutrokine-alpha is only administered when the patient has ≧30 IU/mL of anti-dsDNA antibodies in his/her blood plasma or serum.
4. The method of claim 2 wherein the antagonist of Neutrokine-alpha is only administered when the patient has an ANA titer ≧1:80 and ≧30 IU/mL of anti-dsDNA antibodies in his/her blood plasma or serum.
5. The method of claim 2 wherein the antagonist of Neutrokine-alpha is only administered when the patient has a SELENA SLEDAI score ≧6.
6. The method of claim 2 wherein the antagonist of Neutrokine-alpha is only administered when the patient has less than 90 milligrams/deciliter of C3 complement factor in his/her blood plasma or serum.
7. The method of claim 2 wherein the antagonist of Neutrokine-alpha is only administered when the patient has less than 16 milligrams/deciliter of C4 complement factor in his/her blood plasma or serum.
8. The method of claim 2 wherein the antagonist of Neutrokine-alpha is only administered when the patient is receiving ≧7.5 milligrams/day of prednisone.
9. The method of claim 2 wherein the antagonist of Neutrokine-alpha is only administered when the patient is receiving or had previously received immunosuppressant therapy for the treatment of lupus-related symptoms.
10. The method of claim 2 wherein the antagonist of Neutrokine-alpha is only administered when the patient has an ANA titer ≧1:80.
11. The method of claim 1 wherein the corticosteroid is selected from the group consisting of prednisone, prednisolone, hydrocortisone, methylprednisolone and dexamethasone.
12. The method of claim 1 wherein the corticosteroid is prednisone.
13. The method of claim 12 wherein the quantity of prednisone administered to the patient is reduced by at least 25% to ≦7.5 milligrams/day following administration of the antagonist of Neutrokine-alpha.
14. The method of claim 1 wherein the antibody comprises the amino acid sequences of a set of VH and VL domains selected from the group consisting of:
(a) the VH domain and the VL domain of SEQ ID NO:13;
(b) the VH domain and the VL domain of SEQ ID NO:14;
(c) the VH domain and the VL domain of SEQ ID NO:15;
(d) the VH domain and the VL domain of SEQ ID NO:16;
(e) the VH domain and the VL domain of SEQ ID NO:17;
(f) the VH domain and the VL domain of SEQ ID NO:18;
(g) the VH domain of SEQ ID NO:19 and the VL domain of SEQ ID NO:20; and
(h) the VH domain of SEQ ID NO:21 and the VL domain of SEQ ID NO:22.
15. The method of claim 1 wherein the antibody comprises the amino acid sequences of the VH domain and the VL domain of SEQ ID NO:17.